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INTRODUCTION
Breast cancer is the most common cause of cancer death
and the most common type of cancer in women.
1 The State
of Rio de Janeiro has the highest frequency of this disease in
Brazil.
2 Breast cancer is a significant public health burden. A
combination of genetic factors and individual lifestyle habits
influences breast cancer risk and tumor behavior. Breast
cancer etiology is complex and heterogeneous in its clinical
presentation.
3
TP53 (tumor protein 53) and XRCC1 (x-ray cross
complementing group 1), a tumor suppressor and a DNA
repair gene, respectively, contribute to cancer progression.
The TP53 gene may cause variation in susceptibility to
cancer and give clues about disease progression.
4
Furthermore, several genes involved in DNA repair, such
as XRCC1, carry genetic polymorphisms that may lead to
alterations in DNA repair capacity and affect susceptibility
to various cancers, including breast cancer.
5-7
Two of the most studied polymorphisms in the TP53 gene
are a 16 bp duplication in intron 3 and an arginine to proline
substitution in codon 72 in exon 4. This last variation alters
the structure of the protein p53,
8 resulting in different
biochemical and biological properties.
9 The Arg72 variant
induces apoptosis with about five times more efficiency
than the Pro72 variant.
10,11 However, the Pro72 variant is
more efficient at inducing cell cycle arrest in the G1 phase,
allowing better repair of damaged DNA.
12
XRCC1 is important in the base excision repair process
(BER). The gene has two common polymorphisms in codons
194 (Arg194Trp) and 399 (Arg399Gln) that affect the amino
acid sequence. Codon 194 is located in the linker region that
connects the domains that interact with poly(ADP-ribose)
polymerase (PARP) and DNA polymerase b.
6 It is related to
the binding domains of various proteins including prolifer-
ating cell nuclear antigen (PCNA), apurinic/apyrimidinic
endonuclease 1 (APE1), and 8-hydroxyguanine DNA-
glycosylase (hOGG1). This area is rich in proline, serine,
arginine, and lysine residues. Hence, the change from a
positively charged Arg to a hydrophobic Trp could affect
the binding and efficient repair of DNA.
13,14 Codon 399 is
located in the C-terminal domain of a breast cancer
susceptibility protein 1 (BRCT1) area. Chinese hamster
ovary cell lines that carry non-conservative amino acid
substitutions in this domain, which binds to PARP, exhibit
decreased DNA repair.
15
Here we investigate the possible relationship between the
genetic background of breast cancer patients, including
TP53 and XRCC1 polymorphisms, and tumor clinical
pathological features such as tumor grade, estrogen and
progesterone receptor status, tumor size, and nodal status.
MATERIALS AND METHODS
We recruited 128 unrelated patients between May 2005
and November 2008 at the Department of Mastology,
Fernandes Figueira Institute in Rio de Janeiro (IFF-
Fiocruz/Brazil). All patients were diagnosed with infiltrat-
ing ductal carcinoma (IDC) and answered questions from a
structured questionnaire. Clinicopathological parameters
were obtained from hospital clinical records. We used the
classification of Scarff-Bloom-Richardson modified by
Elston and Ellis as a prognostic parameter and separated
the cases in two groups of increasing tumor aggressiveness:
low/intermediate with an Elston Grade (EG) of I/II and
high with an EG of III. This study was approved by the
Ethics Committee of the Fernandes Figueira Institute and all
participants signed an informed consent.
Genomic DNA was isolated from peripheral blood (n =
99) and non-tumor breast tissue (n = 29) according to
standard procedures.
16 TP53 polymorphisms were detected
by amplifying genomic DNA with primers previously
described.
17 XRCC1 polymorphisms were assessed by
PCR-RFLP as previously described.
18 We were unable to
genotype eight samples for TP53 polymorphisms and three
for XRCC1 polymorphisms. To ensure the quality of our
genotyping results, all genotypes were confirmed by
sequencing after PCR during the standardization of the
method.
Data analysis was performed using the computer soft-
ware GraphPad Instat 3.06 for Windows (San Diego
California, USA). Fisher’s exact test was used to compare
the variables when the number of samples was equal to or
less than 5. A p value , 0.05 was defined as significant. The
observed numbers for each genotype were compared with
those expected for a population in Hardy-Weinberg
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1097Equilibrium by using a goodness of fit Chi-square (x
2) test
applied by the Hardy-Weinberg Equilibrium calculator
program.
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RESULTS
To evaluate the association between breast cancer prog-
nosis and the genetic background of breast cancer patients,
we decided to carry out a case-case analysis on patients with
infiltrating ductal carcinoma (IDC) and with the most
studied variant alleles of the TP53 and XRCC1 genes.
Table 1 presents the demographical and clinicopatholo-
gical data for the 128 patients in our study. The principal
demographic characteristics of our patients are shown in
Table 2 as a function of breast cancer prognosis assessed by
Elston Grade classification (EG). None of the analyzed
characteristics, including age, menopausal status, family
history, or ethnicity, were differentially distributed between
the patients with EG I/II (low/intermediate aggressiveness)
and EG III (high aggressiveness). The allelic frequencies of
the TP53 polymorphisms PIN3 Ins16bp and Arg72Pro of 0.2
and 0.4, respectively, and of the XRCC1 polymorphisms
Arg194Trp and Arg399Gln of 0.07 and 0.25, respectively,
were in accordance with Hardy-Weinberg equilibrium.
20-26
Then we proceeded with the association analysis between
tumor pathological characteristics and the allelic distribu-
tion of the variants (Table 3). We found a statistically
positive association with the 194Trp XRCC1 allele and EG III
(OR = 4.04; 95% CI = 1.30-12.35; p = 0.018).
DISCUSSION
Despite the advances in tumor classification and the
development of new therapies, breast cancer evolution
remains a mystery. TP53 is a very important tumor
suppressor gene and its product, the p53 protein, maintains
DNA stability and normal cellular growth. It is at the center
of several pathways that lead to cell cycle check points,
DNA repair, and apoptosis.
27 The TP53 polymorphisms
PIN3 Ins16bp and Arg72Pro
28-30 and the XRCC1 poly-
morphism Arg194Trp and Arg399Gln are the most studied
variants of each gene.
31,32 However, since these studies are
based on case-control analysis using different populations
and methodologies, the results do not clarify the real load of
the polymorphic variants. Here we report the results of a
case-case study and determine the contribution of TP53 and
XRCC1 polymorphisms to breast cancer prognosis. The
histological grading system proposed by Scarff-Bloom-
Richardson and modified by Elston and Ellis in 1991
33 is
an important independent prognostic factor for invasive
breast tumors. The two groups of patients in our study were
rather homogenous in terms of age and ethnicity and our
genotyping results for XRCC1 variants Arg194Trp and
Table 1 - Sociodemographic of and tumor characteristics
in patients (n = 128).
Variables n (%)
Age (yr)
# 30 2 (1.56)
31 – 40 22 (17.19)
41 – 50 47 (36.72)
51 – 60 29 (22.66)
61 – 70 17 (13.28)
. 70 11 (8.59)
Ethnicity
White 65 (50.78)
Non-White 61 (47.66)
ND
a 2 (1.56)
Menopausal status
Pre-menopausal 58 (45.31)
Post-menopausal 64 (50.00)
ND
a 6 (4.69)
FH breast cancer
Negative 75 (58.59)
1˚ degree* 11 (8.59)
2˚ and/or 3˚ degrees 27 (21.10)
ND
a 15 (11.72)
Tumor size
# 2 cm 57 (44.53)
. 2c ma# 5 cm 40 (31.25)
. 5 cm 3 (2.34)
ND
a 28 (21,88)
Elston Grade
I 28 (21.87)
II 61 (47.66)
III 23 (17.97)
ND
a 16 (12.50)
Lymph node commitment
Negative 45 (35.16)
Positive 49 (38.28)
ND
a 34 (26.56)
ER
Positive 52 (40.63)
Negative 26 (20.31)
ND
a 50 (39.06)
PR
Positive 51 (39.84)
Negative 28 (21.88)
ND
a 49 (38.28)
HER2
Negative 36 (28.12)
Positive 32 (25.00)
ND
a 60 (46.88)
ND
a = no data; ER = estrogen receptor; PR = progesterone receptor;
HER2 = human epidermal growth factor receptor type 2; FH = family
history; *mother and/or sister.
Table 2 - Demographics of the subjects by Elston Grade
status (n = 112).
Variables Elston Grade status p-value
EG III n (%) EG I/II n (%)
Age (yr)
# 30 1 (4.35) 2 (2.25)
31 – 40 1 (4.35) 17 (19.10)
41 – 50 6 (26.09) 35 (39.32) 0.260
51 – 60 9 (39.13) 20 (22.47)
61 – 70 3 (13.04) 8 (8.99)
. 70 3 (13.04) 7 (7.87)
Menopausal status
Pre-menopausal 6 (26.09) 41 (46.07)
Post-menopausal 14 (60.87) 42 (47.19) 0.200
ND
a 3 (13.04) 6 (6.74)
FH breast cancer
Negative 18 (78.26) 50 (56.18)
1˚ degree 0 6 (6.74) 0.230
2˚ and/or 3˚
degrees*
3 (13.04) 20 (22.47)
ND
a 2 (8.70) 13 (14.61)
Ethnicity
White 12 (52.17) 44 (49.44)
Non-White 10 (43.48) 44 (49.44) 0.540
ND
a 1 (4.35) 1 (1.12)
EG= Elston Grade; ND
a = no data; ER = estrogen receptor; PR =
progesterone receptor; FH =family history; * mother and/or sister.
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23-26 Together these observations indicate that
our group of patients is adequate for a case-case study. Our
study revealed a statistically significant relationship
between the Arg194Trp genotype of XRCC1 and Elston
grade III, which indicates a poorly differentiated tumor and,
consequently, is related to increased aggressiveness of the
disease. The role of XRCC1 in efficient BER has already been
well determined
6,15,16 and it is acceptable that some gene
alterations may change its biological activity and play roles
in cancer evolution. A recently published meta-analysis of
37 studies suggests that Arg399Gln is associated with a
trend of increased breast cancer risk.
31 Another meta-
analysis of 10 studies on XRCC1 haplotypes Arg194Trp
and Arg399Gln showed that any conclusions are very
difficult and complex.
32 Overall, no clear indication has
been obtained from such studies. Dufflot et al.
34 investi-
gated the associations of polymorphisms in the genes
XRCC1, XPD, XRCC3, and RAD5 with tumor characteristics
in 94 breast cancer patients. While no polymorphisms were
found to be associated with high tumor grade or estrogen
receptor negativity, the XRCC1 Arg194Trp variant was not
studied. Bewick et al.
35 found that XRCC1 Arg399Gln may
be predictive of the outcome of patients with metastatic
breast cancer treated with DNA damaging chemotherapy.
The same was observed in a study of Portuguese patients.
36
The authors investigated the possible influence of DNA
repair polymorphisms on breast cancer clinicopathological
features and described a possible correlation between the
Gln/Gln genotype of XRCC1 Arg399Gln and less aggressive
tumors, which differs from our observations. Again, the
authors did not analyze the Arg194Trp variant.
In summary, our study reveals that the XRCC1 Arg194Trp
variant is positively associated with breast tumors of Elston
grade III, which is a measure of high tumor aggressiveness.
However, this initial analysis involves a small sample size,
which may contribute to low statistical power. Our findings
indicate that further investigations are needed on a larger
group to clarify the influence of the Arg194Trp XRCC1
polymorphism in breast cancer development and prognosis.
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